Evidence map›Paper›PMID 41593637›Full record

ArticleCritical care (London, England)2026

Endothelial glycocalyx degradation and its association with clinical outcomes and host response aberrations in community-acquired pneumonia across different care settings.

Hui Wang, Erik H A Michels, Mingyang Cai, Joe M Butler, Justin de Brabander, Tom D Y Reijnders, Sebastiaan C Joosten, Timothy E Sweeney, Alex R Schuurman, Tjitske S R van Engelen and 7 more

Registry-linked trialAbstract read
In one paragraph

Article in Critical care (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07715110 (Biological and Immunomodulatory Effect of Hemoadsorption With Macroporous Resin Cartridges in Septic Shock and Refractory Septic Shock Two Parallel Open-label Randomized Pilot Trials.), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07715110 nanot yet recruitingnot on this mapstarted 2027, after this paper: background citation

Biological and Immunomodulatory Effect of Hemoadsorption With Macroporous Resin Cartridges in Septic Shock and Refractory Septic Shock Two Parallel Open-label Randomized Pilot Trials.

TypeinterventionalSponsorMiguel Sanchez GarciaRan2027 to 2029Enrolled16ConditionsSeptic Shock, Vasopressor Resistance, Multiple Organ Dysfunction, Sepsis, HemoperfusionArmsHemoadsorption cartridge
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Hui Wang *Center for Infection and Molecular Medicine (CIMM), Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. hui.nerissa.wang@amsterdamumc.nl.
Erik H A Michels *Center for Infection and Molecular Medicine (CIMM), Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Mingyang CaiData Science and Epidemiology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Joe M ButlerCenter for Infection and Molecular Medicine (CIMM), Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Justin de BrabanderCenter for Infection and Molecular Medicine (CIMM), Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Tom D Y ReijndersCenter for Infection and Molecular Medicine (CIMM), Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Sebastiaan C JoostenCenter for Infection and Molecular Medicine (CIMM), Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Timothy E SweeneyInflammatix Inc, Sunnyvale, CA, USA.
Alex R SchuurmanCenter for Infection and Molecular Medicine (CIMM), Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Tjitske S R van EngelenCenter for Infection and Molecular Medicine (CIMM), Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Bastiaan W HaakCenter for Infection and Molecular Medicine (CIMM), Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Xanthe BrandsCenter for Infection and Molecular Medicine (CIMM), Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Renée A DoumaDepartment of Internal Medicine, Flevo Hospital, Almere, The Netherlands.
Olaf C CremerDepartment of Intensive Care, UMC Utrecht, Utrecht, The Netherlands.
Hessel Peters-SengersCenter for Infection and Molecular Medicine (CIMM), Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
W Joost WiersingaCenter for Infection and Molecular Medicine (CIMM), Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Tom van der PollCenter for Infection and Molecular Medicine (CIMM), Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.

Funding

Chinese Scholarship Council CSC #202208140032Dutch Kidney Foundation Kolff Grant Nr. 19OK009European Commission Horizon 2020, ImmunoSep, grant number 847422European Union's Horizon 2020 research and innovation program 847786 (FAIR)European Union's Horizon 2020 research and innovation program No 847786 (FAIR)
6 · The paper itself

Abstract

backgroundEndothelial glycocalyx degradation has been implicated in the pathogenesis of sepsis. Previous studies linked elevated plasma syndecan-1, an established biomarker of glycocalyx disruption, to mortality in sepsis. We aimed to determine the association of plasma syndecan-1 levels with clinical outcomes and host response changes in patients with community-acquired pneumonia (CAP) with various disease severities.

methodsWe included CAP patients upon presentation in three care settings: emergency department (ED), general ward, and intensive care unit (ICU). We stratified patients in a Normal-Syndecan-1 and an Elevated-Syndecan-1 group based on syndecan-1 levels measured in outpatient controls without infection, and measured 32 biomarkers reflective of five pathophysiological domains involved in sepsis immunopathology: coagulation activation, endothelial cell activation and dysfunction, cytokines, neutrophil degranulation, systemic inflammation and organ damage. We analyzed blood transcriptomes to obtain insight in changes in host response pathways in circulating leukocytes related with glycocalyx disruption.

resultsWe included 50 non-infectious control patients and 384 CAP patients, with samples collected from 95 in the ED, 124 after admission to the general ward, and 165 after admission to the ICU. The Elevated-Syndecan-1 group showed significantly reduced 30-day survival compared to the Normal-Syndecan-1 group (log-rank p < 0.05). The relationship between syndecan-1 (continuous variable) and 30-day mortality was non-linear and independent of comorbidities and disease severity. Most biomarkers were already strongly elevated in the Normal-Syndecan-1 group relative to non-infectious controls, spanning all pathophysiological domains. All biomarkers showed further increases in the Elevated-Syndecan-1 group relative to non-infectious controls, which was also reflected in direct comparisons between the Normal-Syndecan-1 and Elevated-Syndecan-1 groups. Gene set enrichment analysis of blood leukocytes indicated a link between elevated syndecan-1 and increased expression of genes involved in extracellular matrix organization and hemostasis.

conclusionsGlycocalyx degradation, as measured by plasma syndecan-1, shows a non-linear association with mortality in patients with CAP. Key systemic host response changes implicated in sepsis pathogenesis occur prior to detectable glycocalyx degradation in this population.

Indexed as

Community-Acquired PneumoniaGlycocalyxAgedBiomarkersCommunity-Acquired InfectionsFemaleHumansMaleMiddle AgedSyndecan-1BiomarkersSyndecan-1BiomarkersCommunity-acquired pneumoniaEndotheliumSyndecan-1Transcriptome

Identifiers

PMID41593637
PMCPMC12874961

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.